Model Medicines announces preclinical data in study of orally available lead therapeutic (MDL-001) against COVID-19, in partnership with Scripps Research and Mount Sinai, demonstrating efficacy against primary endpoint
- Wednesday, September 22, 2021, 7:00
- Finance
- Add a comment
SAN DIEGO, Sept. 22, 2021 /PRNewswire/ — Model Medicines, an AI/ML pharmaceutical company, today announced preclinical data from a study of their orally available MDL-001 small molecule therapeutic against SARS-CoV-2, the virus that causes COVID-19 disease. In a live virus preclinical…
About the Author
adminasapcorp has written 41794 stories on this site.